# Piramal Enterprises Limited clinical trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Piramal Enterprises Limited as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Piramal Enterprises Limited: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/piramal-enterprises-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 17, 2014 | NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Piramal Enterprises Limited | Phase 1 | Suspended | Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02117336) |
| July 29, 2013 | NCT01910571 | Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of... | Piramal Enterprises Limited | Phase 1 | Completed | Healthy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01910571) |
| July 19, 2013 | NCT01903018 | A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00 | Piramal Enterprises Limited | Phase 2 | Completed | Radiation Induced Mucositis in Head and Neck Cancer | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01903018) |
| June 11, 2013 | NCT01874366 | Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187 | Piramal Enterprises Limited | Phase 1 | Unknown | Overweight, Diabetes Mellitus Type 2 in Obese | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01874366) |
| April 26, 2013 | NCT01841463 | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With... | Piramal Enterprises Limited | Phase 1 | Suspended | Advanced or Inoperable Malignant Melanoma With BRAF Mutation | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01841463) |
| January 30, 2013 | NCT01779336 | Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors | Piramal Enterprises Limited | Phase 1 | Suspended | Advanced Refractory Solid Tumors | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01779336) |
| January 9, 2013 | NCT01764425 | Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy... | Piramal Enterprises Limited | Phase 1 | Terminated | Healthy, Overweight and/or Obese Subjects | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01764425) |
| January 7, 2013 | NCT01762410 | Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors | Piramal Enterprises Limited | Phase 1 | Suspended | Advanced Refractory Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01762410) |
| August 28, 2012 | NCT01674348 | A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes | Piramal Enterprises Limited | Phase 2 | Terminated | Type 2 Diabetes Mellitus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01674348) |
| June 15, 2011 | NCT01373567 | A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis | Piramal Enterprises Limited | Phase 4 | Completed | Plaque Psoriasis | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01373567) |
| April 20, 2011 | NCT01339156 | Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914... | Piramal Enterprises Limited | Phase 1 | Terminated | Acute Dental Pain | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01339156) |
| April 11, 2011 | NCT01333137 | A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer... | Piramal Enterprises Limited | Phase 1 | Terminated | Breast Cancer | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01333137) |
| May 12, 2009 | NCT00899054 | Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer | Piramal Enterprises Limited | Phase 1/2 | Completed | Squamous Cell Carcinoma of Head and Neck | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00899054) |
| May 12, 2009 | NCT00898287 | Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer | Piramal Enterprises Limited | Phase 1/2 | Completed | Pancreatic Cancer | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00898287) |
| April 16, 2009 | NCT00882063 | Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma | Piramal Enterprises Limited | Phase 1/2 | Completed | Relapsed and/or Refractory Multiple Myeloma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00882063) |
| February 13, 2009 | NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | Piramal Enterprises Limited | Phase 2 | Terminated | Mantle Cell Lymphoma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00843050) |
| February 10, 2009 | NCT00840190 | A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies | Piramal Enterprises Limited | Phase 1 | Completed | Solid Tumor, Hematologic Malignancy | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00840190) |
| February 3, 2009 | NCT00835419 | Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression | Piramal Enterprises Limited | Phase 2 | Completed | Melanoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00835419) |
| January 16, 2009 | NCT00824343 | A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and... | Piramal Enterprises Limited | Phase 2 | Completed | Squamous Cell Carcinoma of Head and Neck | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00824343) |
| October 15, 2008 | NCT00772876 | A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies | Piramal Enterprises Limited | Phase 1 | Completed | Cancer | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00772876) |
| October 22, 2007 | NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | Piramal Enterprises Limited | Phase 1 | Withdrawn | Multiple Myeloma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00547404) |
| December 5, 2006 | NCT00408018 | Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | Piramal Enterprises Limited | Phase 1 | Terminated | Neoplasm | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00408018) |
| December 5, 2006 | NCT00407498 | Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | Piramal Enterprises Limited | Phase 1 | Completed | Neoplasm | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00407498) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 11 |
| Terminated | 6 |
| Suspended | 4 |
| Withdrawn | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 3 |
| Melanoma | 2 |
| Overweight | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Multiple Myeloma | 2 |
| Lymphoma, Mantle-Cell | 1 |
| Head and Neck Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Hematologic Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Diabetes Mellitus | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dental supply stores in the United States](https://specstream.ai/data/businesses/dental-supply-stores/united-states)
- [Anesthesiology practices in the United States](https://specstream.ai/data/businesses/anesthesiology-practices/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Doctors' offices in the United States](https://specstream.ai/data/businesses/doctors-offices/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
